$71 million pre-IPO financing round completed by Conkwest

conkwestHey if you didn’t know about it, maybe it is time to add XDATA as part of your market monitoring regimen, 14 days free trials are available here.

A $71 million unregistered equity financing by Conkwest successfully drew to a close. The non-brokered investment round was placed among nine investors. The subscription started almost two weeks ago. A total of five unregistered securities offerings closed by the company raised an estimated $69.17 million.
Conkwest develops and commercializes a product pipeline for the treatment of cancers and viral infections. The company’s products are based on the proprietary cancer-killing cell line Neukoplast (also known as NK-92) – the only cell line that can be commercialized as a direct, scalable, off-the-shelf cancer-killing product. The company is backed by Dr. Patrick Soon-Shiong and Sorrento Therapeutics.
The company is headquartered in Cardiff-by-the-sea CA. Conkwest elected to keep its revenues undisclosed.
The executive team includes Barry J Simon, Patrick Soon-Shiong and Richard Gomberg.
The board of directors includes Hans Klingemann, Henry Ji, John C Thomas, John T Potts, Richard Kusserow, Robert Rosen and Steve Gorlin.The company has raised an estimated total of $140.17 million via private unregistered security offerings.
Offering recap
Status: Completed
Company: Conkwest
Industry: Biotechnology
Amount offered: $71 million
Amount placed: $71 million
SEC filing: Source
First sale: 06-10-2015
Data as of: 06-22-2015

For more information visit www.XDATA.co


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s